Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results
May 10th, 2024
News
All Categories
ACDL
APDN in the News
CertainT®
Coronavirus
Corporate/Financial News
Investors
Large-Scale DNA Production
Linear DNA
mpox
PGx
Press Release
Uncategorized
Vaccines
Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 10th, 2024
APDN Awarded Contract by HDT Bio For Rapid Vaccine Development Program
April 25th, 2024
Applied DNA Announces 1-For-20 Reverse Stock Split
April 22nd, 2024
Applied DNA, Alphazyme Agreement for Scale-Up Linea™ RNAP
March 18th, 2024
APDN to Showcase Linea™ DNA, Linea™ IVT Platforms at World Vaccine Congress
March 14th, 2024
APDN Announces Fourth Quarter Fiscal Year 2023 Financial Results
February 8th, 2024
APDN to Report FQ1’2024 Financial Results on Thursday, February 8, 2024
February 5th, 2024
APDN Announces $3.44M Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
January 31st, 2024